Fiche publication
Date publication
juin 2025
Journal
Clinical lymphoma, myeloma & leukemia
Auteurs
Membres identifiés du Cancéropôle Est :
Dr D'AVENI-PINEY Maud
Tous les auteurs :
D'Aveni M, Fernandes J, Chartier M, Cotté FE, Pagès N, Panes A, Schmidt A, Webert L, Comont T
Lien Pubmed
Résumé
Myelodysplastic syndromes (MDS) are hematological malignancies that primarily affect older individuals, often leading to anemia, which significantly impacts quality of life. Until now, the management of lower-risk MDS (LR-MDS) typically includes erythropoiesis-stimulating agents (ESAs) as first-line treatment, with transfusions becoming necessary in cases of ESA resistance. This study aimed to assess the incidence, prevalence, and clinical outcomes of LR-MDS patients in France, using the French National Health Data System (SNDS).
Mots clés
Blood transfusion, Claims, Epidemiology, Myelodysplasic syndromes, Real-world data analyses
Référence
Clin Lymphoma Myeloma Leuk. 2025 06 18;:
